DE69812177D1 - 3'-epi k-252a derivate - Google Patents

3'-epi k-252a derivate

Info

Publication number
DE69812177D1
DE69812177D1 DE69812177T DE69812177T DE69812177D1 DE 69812177 D1 DE69812177 D1 DE 69812177D1 DE 69812177 T DE69812177 T DE 69812177T DE 69812177 T DE69812177 T DE 69812177T DE 69812177 D1 DE69812177 D1 DE 69812177D1
Authority
DE
Germany
Prior art keywords
epi
derivatives
compounds
survival
enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812177T
Other languages
English (en)
Other versions
DE69812177T2 (de
Inventor
L Hudkins
E Gingrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE69812177D1 publication Critical patent/DE69812177D1/de
Application granted granted Critical
Publication of DE69812177T2 publication Critical patent/DE69812177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69812177T 1997-12-31 1998-12-30 3'-epi k-252a derivate Expired - Lifetime DE69812177T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
PCT/US1998/027644 WO1999033836A1 (en) 1997-12-31 1998-12-30 3'-epimeric k-252a derivatives

Publications (2)

Publication Number Publication Date
DE69812177D1 true DE69812177D1 (de) 2003-04-17
DE69812177T2 DE69812177T2 (de) 2004-01-15

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812177T Expired - Lifetime DE69812177T2 (de) 1997-12-31 1998-12-30 3'-epi k-252a derivate

Country Status (15)

Country Link
US (2) US6093713A (de)
EP (1) EP1044203B1 (de)
JP (1) JP4405667B2 (de)
KR (1) KR20010033737A (de)
CN (1) CN1285836A (de)
AT (1) ATE234308T1 (de)
AU (1) AU1947499A (de)
BR (1) BR9814543A (de)
CA (1) CA2315953C (de)
DE (1) DE69812177T2 (de)
DK (1) DK1044203T3 (de)
ES (1) ES2194385T3 (de)
NO (1) NO20003397L (de)
PT (1) PT1044203E (de)
WO (1) WO1999033836A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2737102A (en) * 2000-12-08 2002-06-18 Ortho Mcneil Pharm Inc Macroheterocylic compounds useful as kinase inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
ATE544455T1 (de) * 2006-12-14 2012-02-15 Tautatis Inc Zusammensetzungen und verfahren für die krebsbehandlung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
KR100201343B1 (ko) 1993-05-28 1999-06-15 바바라 에스 쉴버그 인돌로카르바졸 유도체들의 전립선의 병적상태치료에의 용도
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
CA2170888A1 (en) * 1994-07-04 1996-01-18 Masahiko Kinugawa Process for producing indolocarbazole derivative
WO1997005140A1 (en) 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
AU1947499A (en) 1999-07-19
EP1044203B1 (de) 2003-03-12
BR9814543A (pt) 2000-10-10
DK1044203T3 (da) 2003-07-14
US6093713A (en) 2000-07-25
JP4405667B2 (ja) 2010-01-27
JP2001527079A (ja) 2001-12-25
EP1044203A1 (de) 2000-10-18
CA2315953A1 (en) 1999-07-08
ATE234308T1 (de) 2003-03-15
WO1999033836A9 (en) 2000-09-14
US6451786B1 (en) 2002-09-17
CA2315953C (en) 2010-11-09
NO20003397L (no) 2000-08-31
NO20003397D0 (no) 2000-06-29
ES2194385T3 (es) 2003-11-16
WO1999033836A1 (en) 1999-07-08
KR20010033737A (ko) 2001-04-25
PT1044203E (pt) 2003-07-31
DE69812177T2 (de) 2004-01-15
CN1285836A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
CU23126A3 (es) Inhibicion de kinasa raf usando ureas heterociclicas sustituidas
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
ATE302005T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ES2067813T3 (es) Derivados substituidos de valinamida.
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1992007830A3 (en) Oxindole peptide antagonists
DE69623472D1 (de) Derivate von dolastatin, dreen herstellung un verwendung
BR9608789A (pt) Compostos de tetralina com atividade de mdr
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE69715010D1 (de) Ausgewählte k-252a derivate
DE69812177T2 (de) 3'-epi k-252a derivate
BR0016553A (pt) 2-(1h-indol-3-il)-2-oxo-acetamidas com atividades antitumor
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
DE69623819D1 (de) Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten
DE3584652D1 (de) 2,2,6,6-tetramethyl-4-piperidinyl-derivate und ihre verwendung als lichtstabilisatoren.
MX9603477A (es) Acido micofenolico 4-amino 6-sustituido y derivados con actividad inmunosupresora.
ATE198192T1 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
SU1786802A1 (ru) 2,4-ДИМЕТИЛ-9-ОКСИПИРИДО[1,2-a]ПИРИМИДИНИЙХЛОРИД, ОБЛАДАЮЩИЙ АНТИДЕПРЕССИВНОЙ АКТИВНОСТЬЮ
DE59809929D1 (de) 6-substituierte 1,2,4a,5a,8a,8b-hexahydro- und 1,2,3,4,4a,5a,8a,8b-oktahydro-6h-pyrrolo[3',4':4,5]furo[3,2-b]pyrid-8(7h)-on derivate und ihre verwendung zur bekämpfung von endoparasiten
MX9603483A (es) Acido micofenolico 6-sustituido y derivados.
ES2151820A1 (es) Herbicidas a base de derivados de 1,3-oxazin-4-ona, composiciones que los contienen y procedimiento para su preparacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition